Bo Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Zhao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Guoqing Guo
Department of Anatomy, Medical College of Jinan University, Guangzhou, Guangdong 510630, P.R. China
1 shared publication - Jifeng Zhang
Department of Anatomy, Medical College of Jinan University, Guangzhou 510630, China
1 shared publication - Jiong Li
School of Public Health, North China University of Science and Technology Affiliated People’s Hospital, North China University of Science and Technology, Tangshan, China
1 shared publication - Minghui Tan
State Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Orthopedics, The First Affiliated Hospital of Jinan University, Guangzhou, China
1 shared publication - Yi-Chen Yin
Department of Chemistry, Institute of Biomimetic Materials & Chemistry, Anhui Engineering Laboratory of Biomimetic Materials, Division of Nanomaterials & Chemistry, Hefei National Laboratory for Physical Sciences at the Microscale, Institute of Energy, Hefei Comprehensive National Science Center, University of Science and Technology of China, Hefei, China
1 shared publication - Zhenbin Cai
Department of Orthopaedics The First Affiliated Hospital of Jinan University Guangzhou China
1 shared publication
Latest Publications
- Open Access
- 1 January 2017
- Published by Wiley in Neural Plasticity
- Vol. 2017, 1-11
Endophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β
Amyloid-β(Aβ) plays an important role in Alzheimer’s disease (AD), as oligomeric Aβinduces loss of postsynaptic AMPA receptors (AMPARs) leading to cognitive deficits. The loss of postsynaptic AMPARs is mediated through the clathrin-dependent endocytosis pathway, in which endophilin2 is one of the important regulatory proteins. Endophilin2, which is enriched in both the pre- and postsynaptic membrane, has previously been reported to be important for recycling of synaptic vesicles at the presynaptic membrane. However, the role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR endocytosis is not well understood. In this study, we show that endophilin2 does not affect constitutive AMPAR endocytosis. Endophilin2 knockdown, but not overexpression, resisted oligomeric Aβ-induced AMPAR dysfunction. Moreover, endophilin2 colocalized and interacted with GluA1, a subunit of AMPAR, to regulate oligomeric Aβ-induced AMPAR endocytosis. Thus, we have determined a role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR dysfunction, indicating possible directions for preventing the loss of AMPARs in cognitive impairment and providing evidence for the clinical treatment of AD.
- 1 January 2017
- Published by Wiley in Neural Plasticity
- Vol. 2017, 1-11
Open AccessEndophilin2 Interacts with GluA1 to Mediate AMPA Receptor Endocytosis Induced by Oligomeric Amyloid-β
Amyloid-β(Aβ) plays an important role in Alzheimer’s disease (AD), as oligomeric Aβinduces loss of postsynaptic AMPA receptors (AMPARs) leading to cognitive deficits. The loss of postsynaptic AMPARs is mediated through the clathrin-dependent endocytosis pathway, in which endophilin2 is one of the important regulatory proteins. Endophilin2, which is enriched in both the pre- and postsynaptic membrane, has previously been reported to be important for recycling of synaptic vesicles at the presynaptic membrane. However, the role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR endocytosis is not well understood. In this study, we show that endophilin2 does not affect constitutive AMPAR endocytosis. Endophilin2 knockdown, but not overexpression, resisted oligomeric Aβ-induced AMPAR dysfunction. Moreover, endophilin2 colocalized and interacted with GluA1, a subunit of AMPAR, to regulate oligomeric Aβ-induced AMPAR endocytosis. Thus, we have determined a role of endophilin2 in oligomeric Aβ-induced postsynaptic AMPAR dysfunction, indicating possible directions for preventing the loss of AMPARs in cognitive impairment and providing evidence for the clinical treatment of AD.